Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SBC vs LASE vs NPKI vs SKIN vs INMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SBC
SBC Medical Group Holdings Incorporated

Consulting Services

IndustrialsNASDAQ • US
Market Cap$329M
5Y Perf.-55.6%
LASE
Laser Photonics Corporation

Industrial - Machinery

IndustrialsNASDAQ • US
Market Cap$16M
5Y Perf.-87.1%
NPKI
NPK International Inc.

Oil & Gas Equipment & Services

EnergyNYSE • US
Market Cap$1.30B
5Y Perf.+84.6%
SKIN
The Beauty Health Company

Household & Personal Products

Consumer DefensiveNASDAQ • US
Market Cap$118M
5Y Perf.-38.5%
INMD
InMode Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$882M
5Y Perf.-28.7%

SBC vs LASE vs NPKI vs SKIN vs INMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SBC logoSBC
LASE logoLASE
NPKI logoNPKI
SKIN logoSKIN
INMD logoINMD
IndustryConsulting ServicesIndustrial - MachineryOil & Gas Equipment & ServicesHousehold & Personal ProductsMedical - Devices
Market Cap$329M$16M$1.30B$118M$882M
Revenue (TTM)$178M$7M$287M$296M$375M
Net Income (TTM)$43M$-8M$36M$-6M$87M
Gross Margin73.7%31.1%35.2%64.9%77.8%
Operating Margin33.3%-126.5%11.4%-3.6%21.3%
Forward P/E7.1x29.3x9.6x
Total Debt$12M$5M$37M$379M$13M
Cash & Equiv.$125M$534K$5M$233M$303M

SBC vs LASE vs NPKI vs SKIN vs INMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SBC
LASE
NPKI
SKIN
INMD
StockNov 24May 26Return
SBC Medical Group H… (SBC)10044.4-55.6%
Laser Photonics Cor… (LASE)10012.9-87.1%
NPK International I… (NPKI)100184.6+84.6%
The Beauty Health C… (SKIN)10061.5-38.5%
InMode Ltd. (INMD)10071.3-28.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: SBC vs LASE vs NPKI vs SKIN vs INMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SBC leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. NPK International Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
SBC
SBC Medical Group Holdings Incorporated
The Defensive Pick

SBC carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.76, Low D/E 6.3%, current ratio 3.01x
  • Beta 0.76, current ratio 3.01x
  • Lower P/E (7.1x vs 9.6x)
  • 24.3% margin vs LASE's -105.4%
Best for: sleep-well-at-night and defensive
LASE
Laser Photonics Corporation
The Income Pick

LASE ranks third and is worth considering specifically for income & stability.

  • Dividend streak 2 yrs, beta 1.68
Best for: income & stability
NPKI
NPK International Inc.
The Growth Play

NPKI is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.4%, EPS growth 124.0%, 3Y rev CAGR 12.8%
  • 27.4% revenue growth vs LASE's -13.3%
  • +94.9% vs LASE's -74.1%
Best for: growth exposure
SKIN
The Beauty Health Company
The Quality Angle

SKIN lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer defensive exposure
INMD
InMode Ltd.
The Long-Run Compounder

INMD is the clearest fit if your priority is long-term compounding.

  • 105.0% 10Y total return vs NPKI's 91.5%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNPKI logoNPKI27.4% revenue growth vs LASE's -13.3%
ValueSBC logoSBCLower P/E (7.1x vs 9.6x)
Quality / MarginsSBC logoSBC24.3% margin vs LASE's -105.4%
Stability / SafetySBC logoSBCBeta 0.76 vs SKIN's 2.00, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)NPKI logoNPKI+94.9% vs LASE's -74.1%
Efficiency (ROA)SBC logoSBC13.5% ROA vs LASE's -43.1%, ROIC 72.3% vs -42.1%

SBC vs LASE vs NPKI vs SKIN vs INMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SBCSBC Medical Group Holdings Incorporated

Segment breakdown not available.

LASELaser Photonics Corporation

Segment breakdown not available.

NPKINPK International Inc.
FY 2025
Rental and Service
66.3%$184M
Product
33.7%$93M
SKINThe Beauty Health Company
FY 2025
Consumables
70.7%$213M
Delivery Systems
29.3%$88M
INMDInMode Ltd.
FY 2025
Capital Equipment
100.0%$289M

SBC vs LASE vs NPKI vs SKIN vs INMD — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSBCLAGGINGINMD

Income & Cash Flow (Last 12 Months)

SBC leads this category, winning 3 of 6 comparable metrics.

INMD is the larger business by revenue, generating $375M annually — 52.5x LASE's $7M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to LASE's -105.4%. On growth, LASE holds the edge at +28.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
RevenueTrailing 12 months$178M$7M$287M$296M$375M
EBITDAEarnings before interest/tax$62M-$8M$53M$9M$81M
Net IncomeAfter-tax profit$43M-$8M$36M-$6M$87M
Free Cash FlowCash after capex-$37M-$4M$32M$29M$91M
Gross MarginGross profit ÷ Revenue+73.7%+31.1%+35.2%+64.9%+77.8%
Operating MarginEBIT ÷ Revenue+33.3%-126.5%+11.4%-3.6%+21.3%
Net MarginNet income ÷ Revenue+24.3%-105.4%+12.4%-2.0%+23.3%
FCF MarginFCF ÷ Revenue-20.5%-58.7%+11.1%+9.8%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year-18.3%+28.3%+15.9%-6.7%+5.3%
EPS Growth (YoY)Latest quarter vs prior year+3.2%-7.4%0.0%+38.0%-30.8%
SBC leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

SKIN leads this category, winning 3 of 6 comparable metrics.

At 6.7x trailing earnings, SBC trades at a 82% valuation discount to NPKI's 36.8x P/E. On an enterprise value basis, SBC's 2.9x EV/EBITDA is more attractive than SKIN's 7331.2x.

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Market CapShares × price$329M$16M$1.3B$118M$882M
Enterprise ValueMkt cap + debt − cash$216M$21M$1.3B$264M$593M
Trailing P/EPrice ÷ TTM EPS6.65x-3.29x36.75x-5.69x9.73x
Forward P/EPrice ÷ next-FY EPS est.7.07x29.34x9.64x
PEG RatioP/E ÷ EPS growth rate0.98x
EV / EBITDAEnterprise value multiple2.92x18.49x7331.15x6.88x
Price / SalesMarket cap ÷ Revenue1.60x4.70x4.71x0.39x2.38x
Price / BookPrice ÷ Book value/share1.59x0.90x3.77x2.02x1.33x
Price / FCFMarket cap ÷ FCF19.17x49.58x3.17x10.46x
SKIN leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

SBC leads this category, winning 6 of 9 comparable metrics.

SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-184 for LASE. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SBC scores 7/9 vs LASE's 1/9, reflecting strong financial health.

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
ROE (TTM)Return on equity+17.5%-183.5%+10.3%-9.4%+13.3%
ROA (TTM)Return on assets+13.5%-43.1%+8.5%-1.2%+11.8%
ROICReturn on invested capital+72.3%-42.1%+9.9%-6.8%+13.5%
ROCEReturn on capital employed+37.9%-45.9%+12.7%-4.5%+12.1%
Piotroski ScoreFundamental quality 0–971773
Debt / EquityFinancial leverage0.06x0.49x0.10x6.20x0.02x
Net DebtTotal debt minus cash-$113M$4M$31M$146M-$289M
Cash & Equiv.Liquid assets$125M$533,871$5M$233M$303M
Total DebtShort + long-term debt$12M$5M$37M$379M$13M
Interest CoverageEBIT ÷ Interest expense596.05x-6.60x77.08x0.81x
SBC leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NPKI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in NPKI five years ago would be worth $19,150 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, NPKI leads with a +94.9% total return vs LASE's -74.1%. The 3-year compound annual growth rate (CAGR) favors NPKI at 24.2% vs SKIN's -56.4% — a key indicator of consistent wealth creation.

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
YTD ReturnYear-to-date-25.9%-63.8%+27.6%-35.0%-5.9%
1-Year ReturnPast 12 months+0.3%-74.1%+94.9%-35.9%-2.1%
3-Year ReturnCumulative with dividends-68.9%-76.6%+91.5%-91.7%-60.2%
5-Year ReturnCumulative with dividends-67.8%-72.0%+91.5%-92.9%-63.9%
10-Year ReturnCumulative with dividends-67.8%-72.0%+91.5%-91.6%+105.0%
CAGR (3Y)Annualised 3-year return-32.2%-38.4%+24.2%-56.4%-26.4%
NPKI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SBC and NPKI each lead in 1 of 2 comparable metrics.

SBC is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NPKI currently trades 93.5% from its 52-week high vs LASE's 10.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Beta (5Y)Sensitivity to S&P 5000.76x1.68x1.47x2.00x1.04x
52-Week HighHighest price in past year$5.75$6.77$16.50$2.69$16.74
52-Week LowLowest price in past year$2.97$0.38$7.63$0.76$12.72
% of 52W HighCurrent price vs 52-week peak+55.8%+10.7%+93.5%+33.8%+83.2%
RSI (14)Momentum oscillator 0–10029.938.556.652.139.8
Avg Volume (50D)Average daily shares traded87K1.9M795K760K804K
Evenly matched — SBC and NPKI each lead in 1 of 2 comparable metrics.

Analyst Outlook

LASE leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SBC as "Buy", NPKI as "Buy", SKIN as "Hold", INMD as "Buy". Consensus price targets imply 180.4% upside for SBC (target: $9) vs 14.9% for INMD (target: $16).

MetricSBC logoSBCSBC Medical Group…LASE logoLASELaser Photonics C…NPKI logoNPKINPK International…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$9.00$1.30$16.00
# AnalystsCovering analysts131311
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises20
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.7%0.0%+14.5%
LASE leads this category, winning 1 of 1 comparable metric.
Key Takeaway

SBC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SKIN leads in 1 (Valuation Metrics). 1 tied.

Best OverallSBC Medical Group Holdings … (SBC)Leads 2 of 6 categories
Loading custom metrics...

SBC vs LASE vs NPKI vs SKIN vs INMD: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SBC or LASE or NPKI or SKIN or INMD a better buy right now?

For growth investors, NPK International Inc.

(NPKI) is the stronger pick with 27. 4% revenue growth year-over-year, versus -13. 3% for Laser Photonics Corporation (LASE). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SBC or LASE or NPKI or SKIN or INMD?

On trailing P/E, SBC Medical Group Holdings Incorporated (SBC) is the cheapest at 6.

7x versus NPK International Inc. at 36. 8x. On forward P/E, SBC Medical Group Holdings Incorporated is actually cheaper at 7. 1x.

03

Which is the better long-term investment — SBC or LASE or NPKI or SKIN or INMD?

Over the past 5 years, NPK International Inc.

(NPKI) delivered a total return of +91. 5%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: INMD returned +105. 0% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SBC or LASE or NPKI or SKIN or INMD?

By beta (market sensitivity over 5 years), SBC Medical Group Holdings Incorporated (SBC) is the lower-risk stock at 0.

76β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 163% more volatile than SBC relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — SBC or LASE or NPKI or SKIN or INMD?

By revenue growth (latest reported year), NPK International Inc.

(NPKI) is pulling ahead at 27. 4% versus -13. 3% for Laser Photonics Corporation (LASE). On earnings-per-share growth, the picture is similar: NPK International Inc. grew EPS 124. 0% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NPKI leads at 12. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SBC or LASE or NPKI or SKIN or INMD?

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -73. 8% for Laser Photonics Corporation — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -189. 3% for LASE. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SBC or LASE or NPKI or SKIN or INMD more undervalued right now?

On forward earnings alone, SBC Medical Group Holdings Incorporated (SBC) trades at 7.

1x forward P/E versus 29. 3x for NPK International Inc. — 22. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBC: 180. 4% to $9. 00.

08

Which pays a better dividend — SBC or LASE or NPKI or SKIN or INMD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SBC or LASE or NPKI or SKIN or INMD better for a retirement portfolio?

For long-horizon retirement investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

76)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SBC: -67. 8%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SBC and LASE and NPKI and SKIN and INMD?

These companies operate in different sectors (SBC (Industrials) and LASE (Industrials) and NPKI (Energy) and SKIN (Consumer Defensive) and INMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SBC is a small-cap deep-value stock; LASE is a small-cap quality compounder stock; NPKI is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SBC

Quality Mega-Cap Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Net Margin > 14%
Run This Screen
Stocks Like

LASE

High-Growth Disruptor

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 18%
Run This Screen
Stocks Like

NPKI

High-Growth Compounder

  • Sector: Energy
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 7%
Run This Screen
Stocks Like

SKIN

Quality Business

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Gross Margin > 38%
Run This Screen
Stocks Like

INMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SBC and LASE and NPKI and SKIN and INMD on the metrics below

Revenue Growth>
%
(SBC: -18.3% · LASE: 28.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.